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1. Introduction  
In Europe and the USA, viral aetiologies largely prevail over other causes of myocarditis as 
previously indicated by recent data demonstrating the molecular detection of cardiotropic 
viruses in human cardiac biopsy samples (Kühl et al., 2005a). Clinical presentations of the 
myocarditis range from non-specific systemic symptoms (fever, myalgias, palpitations, or 
exertional dyspnea) to fulminant hemodynamic collapse (5 to 10 cases per million 
inhabitants and per year) and sudden cardiac death (Feldman & McNamara, 2000; Magnani 
& Dec, 2006). 
Acute myocarditis remains a complex and challenging diagnosis in cardiology (Magnani 
& Dec, 2006). This cardiomyopathy is defined histologically by the Dallas criteria as 
an‘‘inflammation of the myocardium’’ associated with necrosis and an absence of 
ischaemia (Aretz et al., 1987; Cooper, 2009; Dennert et al., 2008; Felmann & McNamara, 
2000). The use of the Dallas criteria in the diagnosis of myocarditis is associated with poor 
sensitivity and specificity, mainly because of the sampling error related to the often focal 
distribution of the specific histological lesions in cardiac tissue and because of the 
variability in pathological interpretation (Baughman, 2006; Mahrholdt et al., 2004). 
Moreover, the Dallas classification does not consider local quantification and 
differentiation of inflammatory cells and does not take into account viral infection and 
autoimmune regulation in cardiac tissues (Dennert et al., 2008). To improve the 
histological diagnosis, additional virological and immunological evaluations of cardiac 
tissues are required using immunohistochemical and PCR techniques, which allow 
identification and quantification of inflammatory cells and viral infection markers 
(Dennert et al., 2008). The diagnostic gold standard is endomyocardial biopsy with the 
histological Dallas criteria in association with new immunohistochemical and viral PCR 
analyses of cardiac tissues (Cooper et al., 2007). This new diagnostic approach can lead to 
better identification of the aetiological cause of the myocarditis and can improve the 
clinical management of viral myocarditis. This chapter chronicles the advances in 
understanding the physiopathology of viral acute and chronic myocarditis and in the 
development of new molecular techniques for an accurate and valuable virological 
diagnosis.  
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2. Human viral cardiac infection: proofs of concept and clinical relevance 
Common human pathogenic DNA or RNA viruses can be responsible for acute or chronic 
endomyocardial tissue infection (Andréoletti et al., 1995; 2009; Kühl et al., 2005a). The 
detection of components (DNA or RNA genomes or viral proteins) of these viral agents by 
molecular techniques such as polymerase chain reaction (PCR) and/or 
immunohistochemical techniques demonstrating the viral protein expression in the 
cytoplasm of myocytes, was associated with an inflammation of the myocardium (acute 
myocarditis), arrhythmias, loss of contractility (Andréoletti et al., 2009; Cooper, 2009; 
Dennert et al., 2008). Moreover in serial of human cases, the presence of viral persistence 
was evidenced in the myocardium and associated with a left ventricular systolic dysfunction 
in relation to a reduction in the contractile function of the myocytes (Andréoletti et al., 2000; 
Badorff et al., 2001). Additional proofs of concept were that: (I) a longitudinal clinical 
investigation showed that the type of virus, the clinical presentation and the type of 
histological damage appeared to be related to the clinical course of the cardiac disease; (II) 
longitudinal clinical studies indicated that the immune clearance of the virus during or after 
the acute phase was correlated with an improvement of the left ventricular ejection fraction 
[LVEF] (Kühl et al. 2005b); (III) acute and chronic myocarditis as well as dilated 
cardiomyopathy (DCM) were reproduced in immunocompetent animal models following 
experimental viral infections (Andréoletti et al., 1997; Huber, 1993; Matsumori & Kawai, 
1982). Altogether these clinical and experimental data supported the pathophysiological role 
of several human viruses in the genesis and the evolution of myocarditis and the DCM. 
Although up to 90% of people will be infected by at least one or more of these viruses in 
their life without getting their heart injured with associated clinical signs, only a few 
number will develop clinical symptoms. Therefore, it is highly suspected that a certain 
genetic background either related to immune alterations or to an improved susceptibility to 
viral cardiac infection (viral receptor or co-receptors polymorphisms) may be a prerequisite 
to develop clinical symptoms of myocarditis and/or progression to DCM following virus 
heart tissue infection. In addition, it has been shown that dystrophin mutations may make 
easier the development and progression of myocarditis and cardiac failure during 
coxsackievirus B3 infection, whereas dystrophin and/or sarcoglycan disruption by viral 
proteases account for myocardial injury (Andréoletti et al., 2007; Badorff et al., 2001; Lee et 
al., 2000). Human genetic studies of patients with myocarditis are rare and only 2 reports 
show an association between myocarditis and genetic factors such as HLA-DQ locus and 
CD45 polymorphism (Yajima & Knowlton, 2009). Future clinical investigations should 
therefore focus on the understanding of the underlying genetic susceptibility and related 
immune responses that explain why some patients are susceptible to develop clinical 
symptoms of acute myocarditis following viral infection, whereas other subjects clinically 
recover or progress to an ‘idiopathic’ DCM after the initial phase of the viral cardiac 
infection.  
3. The pathophysiological mechanisms of viral myocarditis 
The current understanding of the immunopathologcial phases of myocarditis derives largely 
from enterovirus-induced myocarditis in murine models (Andréoletti et al, 1997; Cooper et 
al., 2007; Liu & Mason, 2001; Yajima & Knowlton, 2009). During the enterovirus (virus 
Coxsackie B) natural course of infection, the data obtained from experimental murine 
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models allowed the identification of three distinct pathophysiological phases defined as 
acute, sub-acute and chronic myocarditis (Cooper, 2003; Feldman & McNamara, 2000; 
Yajima & Knowlton, 2009) (Figure 1). 
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Fig. 1. Immunopathological phases of viral myocarditis. 
3.1 Acute myocarditis during the initial Virus invasion 
During the period of active viremia, cardiotropic RNA or DNA viruses interact with specific 
vascular endothelial cell receptors before to be translated in the endomyocardial target cells 
to produce viral proteins (Huber, 1993; Li et al., 2000) (Table 1). Mechanisms of viral entry 
into the host cell remains crucial and are of major interest because each of them is putative 
target for novel therapeutics. Before to interact specifically with the virus, expression of 
levels of the virus receptors for CVB3, PVB19, HVV6 (CAR/DAF, P-Antigen/ Alpha5-beta1 
integrin and CD46, respectively) on endovascular endothelial cells of coronary vessels 
modulate the diffusion of these viral agents into the vessels and their subsequent translation 
into the endomyocardial target cells (Khül et al., 2005a; Yajima & Knowlton, 2009). Some 
inflammatory mechanisms as a primary persistent infection by HHV6 or PVB19 may 
modulate cell membrane receptors and /or immune suppression and preventing virus 
clearance; altogether these mechanisms could facilitate an endomyocardial super infection 
by a second viral agent as described in 27 % of virus positive DCM patients (Khül et al., 
2005a) (Table 1). 
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Common 
cardiotropic 
Viruses 
 
Detection 
Methods 
 
 
Cardiovascular 
tissular 
Localization 
 
 
Cellular Receptor  / 
Coreceptor Involved
 
References 
 
 
Adenovirus EM 
Cardiomyocytes, 
fibroblasts, 
endothelial cells 
CAR / Integrins 
(┙v┚3 and ┙v┚5) 
Shi et al., 2009; Wickham 
et al., 1993 
Enterovirus/ 
Coxsackievirus B IHC, ISH Cardiomyocytes CAR / DAF 
Shi et al., 2009; Coyne & 
Bergelson, 2006 
Parvovirus B19 
ISH, LCM + 
PCR 
Endothelial cells, 
cardiomyocytes 
Gb4Cer / 
Integrin (┙5┚1); 
Ku80 autoantigen 
Bultmann et al., 2003; 
Bönsch et al., 2010 
Human Herpes 
Virus 6 
In vitro 
Infection Endothelial cells CD46 
Caruso et al., 2002; Santoro 
et al., 1999 
Cytomegalovirus ISH Cardiomyocytes 
Integrins ( ┙2┚1,  
┙6┚1, and  ┙v┚3) 
Feire et al., 2004; Kyto et 
al., 2005 
Epstein-Barr 
Virus ISH Lymphocytes B CD21 
Chimenti et al., 2004; 
Takano et al., 2008 
Influenza Virus ISH 
Macrophages, 
Lymphocytes ND Cioc et al., 2002 
EM indicated electron microscopy; IHC, immunohistochemistry ; ISH, in situ hybridrization; LCM + 
PCR, polymerase chain reaction using tissue samples isolated with laser capture microdissection; CAR, 
coxsackie and adenovirus receptor; DAF, decay accelerating factor ; CD, cluster of differentiation and 
ND, not determined 
Table. 1. Cardiovascular tissular localization of common cardiotropic viruses and local 
suspected cellular receptors involved in the process of infection. 
At the beginning of human viral infection, the first line of immune defense consists in the 
innate immune response (NKT cells, monocytes and macrophages). Cell-mediated 
immunity also plays an important role in viral clearing. Cytotoxic (CD8+) cells recognize 
degraded viral protein fragments that are presented by major histocompatibility-complex 
class I antigens on the myocyte surface (Seko et al., 1990) (Figure 1). The Toll-like receptors 
located at the surface or inside of dendritic cells (more particularly the Toll-like-receptors 4, 
7, and 8 in the case of virus Coxsackie B infection) could recognize certain viral proteins or 
genomic and then activate intracellular signals (NF-kB pathways) responsible for a fast 
synthesis and secretion of pro-inflammatory cytokines as interferons and chemokines and 
also nitric oxide (Ayach et al., 2003; Kawai, 1999; Matsumori et al., 1994) (Figure 1). The pro-
inflammatory cytokines then attract and activate many immune system cell lines to the site 
of the viral infection and they are directly responsible for cardiac myocytes lysis and also for 
lost of cardiomyocyte contractility and apoptosis cell-dead (Feldman & McNamara, 2000; 
Ventéo et al., 2010) (Figure 1).  
3.2 Sub-acute myocarditis with an activation of the immune system and the 
development of autoimmunity 
The activation of the immune system at the time of the viral invasion reaches to the 
initiation of specific cellular immunity response and to the immune shift towards a specific 
immune response. The viral particles are captured by antigen processing cells (APC) and 
degraded within the Golgi apparatus before being presented at the cell surface by the major 
histocompatibility complex class I (MHC class I) to the CD8+ lymphocytes. These primed T 
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cells capable to detect the viral antigen will destroy the infected cardiac cells through 
cytokines or perforines secretion (Kawai, 1999, Matsumori et al., 1994). In addition, some 
myocardic cellular antigens of the host present can share epitopic similarities (molecular 
mimicry) with viral antigens therefore inducing an autoimmune trait that can sustain the 
inflammatory response and therefore the chronic inflammation phases (Figure 1). This sub-
acute phase is known to be linked to autoimmune responses as many patients produce auto-
antibodies and auto-reactive T cells against heart proteins (Domenico & Gaetano, 2006; 
Feldman & McNamara, 2000) and the amplification of this phenomenon can lead to the 
destruction of cardiomyocytes. The mechanisms linking enteroviral infection with sub-acute 
myocarditis, relapses and post inflammatory heart failure could be mainly mediated by 
dendritic cells (DCs) that are specialized in antigen processing and presentation and most 
important in priming of T cells within lymph nodes. The EV-induced autoimmune 
myocarditis may require activation of these cells via CD40 with Toll like receptors (TLRs 3, 
4, 7) or RNA helicases (RIG-I, MAD-5) co-stimulation (Kramer et al., 2008). Moreover in 
human infections, it is clear that human enteroviruses (HEVs) can escape from 
immunological system by decreasing the specific functions of immunity cell system 
(Oldstone, 2006). Recently it has been demonstrated that Enteroviruses could infect and 
consequently modify the maturation process and some specialized functions of DCs 
(Kramer et al., 2007). Therefore, Enteroviruses or some of its components could activate or 
decrease some DCs functions acting as modulators of innate response system or 
autoimmunity (Kramer et al., 2007). 
3.3 Chronic myocarditis with a potential evolution to the dilated cardiomyopathy 
clinical stage 
After the active virus replication resulting in acute and sub acute myocarditis phases, the 
pathological signs of myocarditis generally disappeared and the destroyed myocytes are 
replaced by diffuse fibrosis (Dec et al., 1985) (Figure 1). At this stage, a progressive heart bi-
ventricular dilatation with a cardiac failure can be observed and has been related to cardiac 
persistent or chronic viral replication mechanisms (Andréoletti et al., 2000; Badorff et al., 
1999) (Figure 1). This persistent or chronic viral infection could be related with various 
cardiac cell dysfunctions as impairment of Ca+ efflux in cardiomyocytes and of loss of cell 
contractility, apoptosis balance deregulation, cleavage of dystrophine, modulation of 
cellular signalling pathways or alteration of the extracellular matrix (Andréoletti et al., 2009; 
Dennert & McNamara, 2009; Kawai, 2009; Khül et al., 2008a).  
4. The Virological mechanisms of cardiac infection 
4.1 Acute viral myocarditis  
Viruses generally infect human beings by fecal-oral (enteroviruses, parvovirus B19, 
Herpesviruses) or respiratory routes (enteroviruses, influenza viruses A & B, parainfluenza 
viruses I II III) and they usually perform a first phase of multiplication into the airway 
epithelial cells of the higher respiratory tract or tonsils; this can be followed by a potential 
rapid invasion of the lower respiratory tract as observed during influenza virus infection. 
After this initial and local replication phase, the viruses can diffuse by lymphatic way to the 
general circulation (viremic phase) allowing them to reach the cardiac tissues. In the heart, 
the virus infects and replicate actively into the cardiac myocytes but also into the cardiac 
fibroblasts that can play the role of reservoir cells for a persistent infection (Andréoletti et 
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al., 2009). During this active phase of replication, the development of the classical clinical 
signs of myocarditis is usually observed (Andréoletti et al., 2007; Magnani & Dec, 2006).  
4.2 The chronic persistent viral Infection in heart tissues 
4.2.1 The enterovirus model 
After the acute myocarditis phase, persistence can be observed as described during human 
cardiac enterovirus (EV) infection. In some previous published studies, detection of viral 
genome has been demonstrated in patients with myocarditis and in patients with DCM, but 
it is unusual that replication competent virus can be isolated from the myocardium in 
patients with myocarditis (Andréoletti et al., 2009; Chapman & Kim, 2008a; Copper, 2009). 
The concept that EV endomyocardial persistent infections are the etiological cause of a 
subset of idiopathic DCM cases is supported by the detection of enterovirus genomic 
sequences and enteroviral capsid protein VP1 in up to 35 % of explanted heart tissues from 
end-stage DCM patients (Andreoletti et al. 2009; Li et al., 2000). In a previous published 
study, we observed that enteroviruses can persist with or without active viral replication in 
cardiac tissue of patients with end-stage dilated cardiomyopathy (Andréoletti et al., 2000). 
Enterovirus genome was detected in 25 of 70 patients with IDCM and, of these patients 
positive for genomic RNA, only 3 exhibited antigenomic RNA and VP1 antigen that 
demonstrated active viral replication, whereas 22 had latent infection characterized by the 
absence of antigenomic RNA associated with or not with VP1 antigen expression. No viral 
component was detected in control subjects (Andréoletti et al., 2000). These findings 
demonstrated that a small percentage of patients with end-stage chronic cardiac diseases 
had active enterovirus replication in their myocardium. Moreover, we demonstrated that 
enteroviral capsid protein VP1 was present in myocardial tissues from some patients with 
dilated cardiomyopathy and suggested that the pattern of VP1 detection may correlate with 
disease stage and severity. These data suggested that viral protein synthesis might be 
involved in persistent enterovirus infection in the pathogenesis of DCM (Li et al., 2000). It 
was observed that the ratio of positive- to negative-strand enteroviral RNA was greater with 
active virus replication than with persistent virus infection where a viral capsid protein 
synthesis activity was also evidenced in heart cardiac tissues (Andréoletti et al., 2000; Li et 
al., 2000, Chapman & Kim, 2008a). This slow viral replication could be explained by the 
existence of 5’NC genomic deleted viral forms that could be related to the development of 
slow replicating viral forms in heart tissues (Chapman et al., 2008b). As persistent 
expression of CVB proteins and 2Aprotease (2Apro) alone are sufficient for induction of 
cardiomyopathy in the mouse and as detection of HEV TD genomes in adult human heart 
disease is likely due to persistent HEV TD genomes, there is now a new hypothetical 
mechanism to link of acute viral myocarditis with postviral DCM (Chapman et al. 2008b). 
4.2.2 The Parvovirus B19 model 
Concerning the Parvovirus B19 virus, a persistent infection was detected in intra-cardiac 
endothelial cells of small arterioles and veins of patients with chronic cardiomyopathies by 
in situ hybridization and PCR techniques. This persistent PVB19 infection associated with a 
low viral replication may be associated with endothelial dysfunction, impairment of 
myocardial microcirculation, penetration of inflammatory cells and secondary myocyte 
necrosis. (Duechting et al., 2008). The molecular mechanisms responsible for the reactivation 
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of latent parvovirus B19 infection, the influence of immune activation triggering parvovirus 
B19 replication and chronic myocarditis, and immune-independent viral pathogenesis 
remains to be assessed (Bock et al., 2010).  
4.3 The chronic latent viral cardiac infections 
In cases of herpesviruses (HSV1, HSV-2 , HCMV, HHV-6) cardiac infection a latent phase can 
occur subsequently to the acute phase of infection as demonstrated in a mice model 
(Grodums & Zbitnew, 1976). During this HSV experimental latent infection, HSV-DNA can 
be identified as agents of a persistent heart infection in cardiomyocytes, fibroblasts or 
Schwann cells, which has be seen in unmyelitinated axons in murine heart tissues. In human 
subjects, CMVH was detected in cardiomyocytes and in cardiac fibroblasts of patients with 
histological proven myocarditis (Schönian et al., 1995). Moreover, it was not possible to 
detect viral mRNA coding for structural proteins known as late proteins but only mRNA 
coding for viral enzymatic proteins (early proteins) related to the regulation of viral 
replication or associated with the HCMV DNA replication (Lenzo et al., 2002) Whatever, the 
cellular sites as well as the mechanisms of latency and reactivation of the herpesviruses (EBV, 
HCMV and HHV6) in human heart tissues remain to be assessed (Andréoletti et al., 2009; 
Cooper, 2009; Dennert et al., 2008).  
5. Viral causes for human acute or chronic myocarditis 
Human Enteroviruses, (picornaviridae), specifically Coxsackie group B serotypes, Parvovirus 
B19, HHV6 of the B type and the adenovirus are the most frequently etiological viral agents 
implicated in the acute myocarditis of the child or the young adult (<35 year-old) 
(Andréoletti et al., 2009; Bowles et al., 2003; Feldman & McNamara, 2000; Kühl et al., 2005b; 
Magnani & Dec, 2006) (Table 2). Moreover HHV-1, Adenovirus, myxoviruses and also 
paramyxoviruses including respiratory syncytial virus (RSV), influenza and parainfluenza 
strains can also induce an acute infection of cardiac tissue as previously demonstrated in 
reported acute myocarditis cases developed in immunocompetent patients (Bowles et al., 
2003; Dennert et al., 2008). Other viruses as EBV or CMV are also associated with this 
pathology after heart transplantation. HIV or HCV can be also etiological agents of 
myocarditis (Matsumori et al., 2006; Sudano et al., 2006) (Table 2).  
Recent data showed that it was possible to detect viruses in 71% of the cases of acute 
myocarditis using molecular techniques for the virological analysis of cardiac biopsy 
samples (Table 2) (Kühl et al., 2003). Co-infections were found in more than 12% of the 
cases, generally associating HHV6 and Parvovirus B19. HHV6 seems to be an important 
cofactor of myocarditis due to Parvovirus B19. HHV6 may enhance the pathogenicity of 
Parvovirus B19 through alterations of the extracellular matrix and modulation of the 
expression levels of the PVB19) receptor (P-antigen) on endothelial cells facilitating 
infections of the coronary vascular endothelium (Table 2) (Kühl et al., 2005a).  
Concerning chronic myocarditis, there is no clinical data from transverse or longitudinal 
studies indicating the incidence of various viral causes of cardiac infection. However, viral 
persistence in the myocardium was associated with ventricular dysfunction whereas viral 
genome clearance was related to the hemodynamic improvement (Kühl et al. 2005a, 2005b). 
As in the cases of acute myocarditis, recent studies showed the interest to test a broad panel 
of cardiotropic viruses at the DCM stage. Thus, in a case series of 245 patients with clinically 
suggested DCM, one or more viruses were detected in 67% of the cases (Table 2) (Kühl et al., 
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Human cardiotropic 
Viruses 
 
Acute 
myocarditis 
 
Dilated 
Cardiomyopathy
 
References 
Human enteroviruses 14 - 33 % 8 - 35% 
Li et al. 2000; Andréoletti et 
al. 2000, Kühl et al. 2005a, 
2005b 
Parvovirus B19 
(PrvB19) 
<1 - 37% 51% Kühl et al. 2005a, 2005b 
Human Herpes Virus 6 
(HHV6) 
11% 6-22% 
Kühl et al. 2005a, 2005b, 
Mahrhodt et al.2004 
Adenovirus 8.1 - 23% 2 - 12% 
Kühl et al. 2005a, 2005b, 
Bowles et al. 2003 
Multiple infections 
(60% of cases = 
PrvB19+HHV6) 
12% 27% Kühl et al. 2005a, 2005b 
    
Rare viral causes in 
immunocompetent 
patients* (non restrictive 
list) 
   
Cytomegalovirus 
(CMVH) 
3% 0.8% Kühl et al. 2005a, 2005b 
Epstein Barr Virus 
(EBV) 
<1% 2% Kühl et al. 2005a, 2005b 
Herpes Simplex Virus 
(HSV) 
<1% - Kühl et al. 2005a, 2005b 
Influenza viruses <1 - 2% - Kühl et al. 2005a, 2005b 
Hepatitis C - - - 
HIV - - - 
(-) Not determined; * Prevalence determined in cases of solid organ transplantation. 
Table. 1. Prevalence of viruses detected by molecular biology-based techniques in cardiac 
tissue samples taken from patients with acute myocarditis or dilated cardiomyopathy.  
2005a). Moreover in these patients, the absence of associated myocardial inflammation 
suggests that viral persistence can be responsible for a modulation of the immune response, 
which would be decreased from the beginning of the chronic phase of myocarditis (Kawai, 
1999; Yajima & Knowlton, 2009). 
6. Diagnosis of viral causes of myocarditis 
Many common human viruses can be the etiological cause of acute or chronic myocarditis in 
children or young adult patients (Andréoletti et al., 2009). Because of the large number and 
serotypes of human viruses potentially responsible for cardiac infection the clinical interest 
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of viral serological assay remains of a limited interest in clinical practice (Mhafoud et al., 
2011). A recent European study demonstrated that virus serology has no relevance for the 
diagnosis of myocardial infection in young adults; this study indicated that comparatively 
to the molecular analysis of endomyocardial biopsy tissues, the positive predictive value 
was 25% and that the negative predictive value was 49% (Mhafoud et al., 2011).Therefore 
the etiological diagnosis of viral myocarditis is based on the detection of the viruses or viral 
components (proteins or genomes) in peripheral blood samples at the time of viremia phase 
(clinically characterized by fever), but also at the entry and the excretion sites (throat, urine 
and stool samples), and in heart tissue samples that corresponds to the organ site of viral 
replication. Therefore, endomyocardial biopsy remains the gold standard for unequivocally 
establishing the histopathological and virological diagnosis of unexplained 
cardiomyopathies as acute or chronic myocarditis (Li et al., 2000; Mahrholdt et al., 2004). Its 
clinical impact on prognosis and treatment largely depends on establishing a rapid and 
standardized set of diagnostic methods including histopathological and virological analyses 
of endomyocardial tissue taken by endomyocardial biopsy (Aretz et al., 1987; Mahrholdt et 
al., 2004). 
6.1 Endomyocardial biopsy (EMB) 
As recommended by the Heart Failure Society of America and the Heart Failure Association 
of the European Society of Cardiology, the implementation of a right or left ventricular EMB 
is indicated in the case of acute symptoms of heart failure refractory to standard 
management, a substantial worsening of ejection fraction despite optimized 
pharmacological therapy, the development of hemodynamically significant arrhythmias, an 
heart failure with concurrent rash, fever, or peripheral eosinophilia, an history of collagen 
vascular disease such as systemic lupus, erythematosus, scleroderma, or polyarteritis 
nodosum, and a new-onset cardiomyopathy in the presence of known amyloidosis, 
sarcoidosis, or hemochromatosis when no obvious cause, in particular ischemic, could be 
established (Mahrholdt et al., 2004). EMB remains the gold standard for unequivocally 
establishing the diagnosis of unexplained cardiomyopathy Li et al., 2000). However, its 
sensitivity and its specificity are limited by the often-focal distribution of the specific 
histological lesions (Baughman, 2006).  
Cardiac biopsy samples should be obtained in more than one area of the right ventricular 
septum and the number of samples should range from 5 to 10 of a volume from 1 to 2 mm3. 
Five of these samples should be fixed in neutralized 10% formalin or 10% PFA; five should 
be flash-frozen or placed immediately conserved at –80°C  to perform further classical or 
molecular virological techniques (Mahrholdt et al., 2004). Interestingly, it has been recently 
demonstrated that there were no differences in the number of positive left ventricular-EMB, 
right ventricular-EMB, or left ventricular- and right ventricular-EMB findings when related 
to the site of cardiovascular magnetic resonance– based late gadolinium enhancement. 
Preferential biopsy in regions showing late gadolinium enhancement on cardiovascular 
magnetic resonance does not increase the number of positive diagnoses of myocarditis. 
(Yilmaz et al., 2010). 
6.2 Histopathological evaluation of cardiac biopsy samples 
Histological evaluation of cardiac biopsies from patients with clinically suspected 
myocarditis is routinely done according to the Dallas criteria (Cooper, 2009). Since 
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myocarditis is a focal disease, 4 to 5 biopsy samples obtained in more than one area of the 
right ventricular septum should be analysed for light microscopic examination and 
immunohistochemical assays (Mahrholdt et al., 2004). For routine light microscopy 
examination, EMB tissue is embedded in paraffin and serial sections are obtained and 
stained with hematoxylin, eosin. Masson trichrome or Sirius red can be useful for a better 
evaluation of the fibrosis (Cooper, 2009). Additional slides have to be performed for 
subsequent immunohistochemical assays (Aretz et al., 1987; Mahrholdt et al., 2004). 
To improve the histological diagnosis, additional immunological evaluation of cardiac 
tissues is required with immunohistochemical techniques allowing quantification, 
identification, and differentiation of inflammatory cells (Aretz et al., 1987). Criteria for 
immunohistological diagnosis in the EMB of inflammatory cardiomyopathy is specified 
quantitatively as >14 infiltrating leukocytes/mm², preferably T-lymphocytes or activated T-
cells. If foci of T-lymphocytes are present, active myocarditis can be diagnosed due to the 
nature of the infiltrate even when the critical level of 14 leukocytes/mm² is not reached 
(Aretz et al., 1987). Subsequent biopsies will allow reliable follow-up of the myocarditis with 
a semi-quantitative evaluation of myocardial inflammation, necrosis and healing. If the 
levels of inflammation appear unchanged from the most recent previous cardiac biopsies, 
the term ongoing (or persistent) myocarditis will be used (Cooper, 2009). 
Finally in cases of clinically suspected viral myocarditis or unexplained cardiomyopathy, 
Dallas criteria have to be associated with classical immunohistological assays for the 
identification of inflammatory cells and also for the detection of viral capsid or early or late 
antigens in EMBs  (Andréoletti et al., 2009). 
6.3 Classical virological analyses of samples taken from patients with myocarditis 
The etiological diagnosis of viral myocarditis, specifically during the acute phase 
corresponding to the acute viral infection, is based on the detection of the viruses or viral 
components (proteins or genomes) in heart biopsy tissue samples and additionally to 
detection of viral genomes in peripheral biological samples as whole blood (viremia) , throat 
(classical entry site of viruses) and urine and stool samples. The direct virological techniques 
are now based on molecular biology (PCR, RT-PCR) and immunohistochemical assays for 
EMBs. By comparison, the contribution of viral serological assays to the clinical diagnosis of 
acute or chronic myocarditis is relatively poor and the serological assays are of interest only 
for a late and retrospective diagnosis of viral myocarditis (Dennert et al., 2009). However, 
Hepatitis C and B and HIV serologies should be systematic in a patients suffering from 
acute or chronic myocarditis (Aretz et al., 1987). 
Using classical molecular techniques, the genome of enteroviruses, adenoviruses, human 
hepatitis viruses or herpesviruses can be detected in 40 to 70 % of the cardiac tissues of 
patients suffering from an histological–proven acute myocarditis (Table 1) (Badorff et al., 
1999; Gravanis & Sternby, 1991). These molecular techniques must be performed on a pool 
of several EMBs taken, from different heart tissue areas that should be extracted together in 
order to optimize the efficiency of viral nucleic acid recovery rates (Mahrholdt et al., 2004). 
Some specialized laboratories use real-time PCR assays that allow a quantitative approach 
to estimate viral loads of the majority of cardiotropic viruses. However, no published data 
exist on the clinical value of real-time PCR viral loads and the determination of clinical 
thresholds that could be capable to differentiate a viral cardiac replicative infection from a 
persistent or latent viral endomyocardial infection. Only one published study reported a 
mean value of 500 copies of PVB19 genome per one microgram of extracted DNA as the 
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clinical threshold related to a significant endomyocardial inflammation (Bock et al., 2010) 
Only the strategy of associated classical RT-PCR and PCR assays or PCR-microarrays for the 
detection of all the most common cardiotropic viruses can provide an accurate diagnosis of 
viral myocarditis. However, sampling error in this focal cardiac disease and the frequent 
late timing of EMB can also hamper the clinical application of these molecular assays after 
disease onset. Finally, a positive RT-PCR or PCR result can provide an etiological diagnosis 
and have to be evaluated into the clinical context, whereas negative PCR results do not 
exclude a viral-related cardiac disease. Moreover, the only use of the molecular techniques 
cannot distinguish an active from a persistent viral cardiac infection. Therefore during the 
clinical course of myocarditis, the immunohistochemical detection of enterovirus, adenovirus 
or parvovirus B19 capsid proteins or herpesviruses late proteins is necessary in order to 
differentiate a viral cardiac infection with replication activities from a persistent or latent 
cardiac infection (Matsumori et al, 2006; Sudano et al., 2006). In the present time, the 
combination of molecular and immunohistochemical assays on cardiac tissue samples 
provides a reliable diagnostic strategy for a complete diagnosis of a potential viral-induced 
acute or latent/persistent cardiac infections. The direct detection of viral genomes in 
association with the immunohistochemical detection of viral capsid or late proteins in 
cardiac tissues is crucial to characterize the phase of the viral infection (acute or 
persistent/chronic) and therefore to specifically adapt the therapeutic strategies (Andréoletti 
et al., 2009; Badorff et al., 1999; Gravanis & Sternby, 1991; Sudano et al., 2006). 
6.4 Use of new techniques for the virological analyses of heart samples taken from 
patients with myocarditis or dilated cardiomyopathy 
In the present time, classical real time PCR techniques allow a reliable qualitative detection 
of viral genomes in cardiac tissues of patients in cases of medical diagnosis of hypokinetic 
cardiomyopathies (Cooper, 2009) or in series of post mortem or explanted heart tissues 
(Andréoletti et al., 2000, Dennert et al., 2008; Cooper, 2009). The two critical points remain 
the number of endomyocardial biopsies (5 to 10) their anatomic origin as well the extraction 
phase that determine the quality of and the sensitivity of detection of the DNA or RNA viral 
genomic sequences (Cooper, 2009). The standardization of the extraction phase is now 
possible by the use of semi-automated or totally automated use of standardized procedure 
using certified available systems (Renois et al.,2010). A pool of several EMBs taken, from 
different heart tissue areas have to be extracted together in order to optimize the efficiency 
of viral nucleic acid recovery rates (Copper, 2009; Dennert et al., 2008). Combination of such 
automated extraction procedures with monoplex or multiplex classical real time RT PCR 
techniques can allow an international standardization of the molecular qualitative or 
quantitative detection of DNA or RNA cardiotropic viruses in human endomyocardial 
biopsies. 
It is now possible to use new multiplex amplification assays followed by a microarray 
hybridization system allowing a simultaneous of 9 to 12 cardiotropic viruses (herpesviruses 
or human enteroviruses) in a single analysis. We experienced this system in our laboratory 
and we observed that multiplex PCR-microarray assay provided a consistently robust 
qualitative detection of at least 9 viruses in on reaction tube (HSV1, HSV2, CMVH, VZV, 
HHV6, HHV7, HHV8, enteroviruses species A & B) (unpublished data). We showed that 
there was a 100% concordance for positive virus detection results and that the theoretical 
limits of detection were as low as 10 genome copies for CVB3 Nancy per microgram of total 
RNA. Because the system used intergrated a internal extraction and ampliciation control, it 
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should be assumed that negative results indicate the absence of targeted viruses (Figure 2). 
The use of such systems could help to standardize the diagnostic detection of cardiotropic 
viruses in endomyocardial tissues and can be routinely used for a rapid viral detection and 
screening; however this system is only qualitative and cannot provide semi-quantitative or 
quantitative viral load values for each detected virus. Therefore in cases of a positive viral 
detection in cardiac tissues we currently use a second quantitative approach using 
standardized classical real time viral quantitative detection assays. The obtained results are 
standardized in viral genome copies per one ug of extracted DNA (Andréoletti et al., 2009, 
Bock et al., 2010) (Figure 2). 
 
 
Fig. 2. Detection of a dual Human Enterovirus and HHV6 cardiac infection using a PCR-
DNA microarray system in an adult patient with an idiopathic dilated cardiomyopathy.  
A. PCR-DNA microarray system (CLART® Entherpex,Genomica, Madrid, Spain) allowing the 
detection and typing of 8 Human Herpes viruses and of the Human Enterovirus (HEVs) group. The 
study patient is co-infected by HHV-6 and Human Enterovirus  (Poliovirus, Echovirus or 
Coxsackievirus).B. Quantitative detection of HEVs in biopsy heart tissues from the same  idiopathic 
DCM patient using classical real time PCR assay and confirming the HEV cardiac infection 
Amplification curves obtained for positive and negative controls and one HEV positive DCM patient 
X. Positive control corresponded to the  CVB3 Nancy strain; Negative control corresponded to 
healthy heart tissue; CT, cycle threshold.  
A new strategy for the molecular detection of cardiac viral infections couples broad-range 
PCR amplification to electrospray ionization/ mass spectrometry analysis (PCR/ESI-MS). 
Previous versions of this method were known commercially as the Ibis T5000 and the 
current commercial hardware platform that conducts the MS analysis is now known as the 
Abbott PLEX-ID (Ecker et al., 2008). This technique uses primers designed to genomic 
regions highly conserved regions across viral domains of life. The method was initially 
developed for the identification of viruses, including previously unknown or unculturable 
viral agents in samples where multiple microbes may be present, primarily for biodefense 
applications (Ecker et al., 2008). It is now being developed for diagnosis of human cardiac 
infections by our team (Figure 3). Preliminary data obtain from 52 heart biopsy samples 
taken from 24 patients with idiopathic DCM showed a Kappa test correlation of 0.7 +/- 0.22 
between PleX-ID detection system and 8 monoplex Q rt-PCR assays. Among the 24 study 
Aligment Markers
Amplification Control
HHV-6 
Human  
ENTEROVIRUS
Positive Control 
Negative 
Patie
A B. CT = 37 
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patients, our findings indicated that EV (12.5%), PVB19 (12.5%) and dual EV-PVB19 (25%) 
infections were identified as major potential etiological causes of idiopathic DCM (personal 
data; not shown). Moreover this new system allowed a rapid semi-quantitative detection of 
EV associated with a genotyping identification of the EV strains (CVB3 or CVB5; personal 
data not shown) (Figure 3) .Finally this system allows a rapid and valuable quantitative 
detection and genotyping identification of common viruses in heart tissues and can be used 
in clinical practice for an accurate diagnostic of viral cardiac infection. 
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Fig. 3. Detection of parvovirus B19 (panel A) or coxsackievirus B3 (Panel B) in cardiac 
tissues of two patients (A and B) with idiopathic  dilated cardiomyopathy using broad-
range PCR amplification followed by ionisation and mass spectrometry analysis (personnal 
data 2011). 
7. Conclusions and therapeutic perspectives  
To improve histological diagnosis of viral myocarditis, additional virological evaluation of 
cardiac tissues is required with immunohistochemical and polymerase chain reaction (PCR) 
techniques allowing identification and quantification of viral infection markers. The 
diagnostic gold standard is endomyocardial biopsy (EMB) with the histological Dallas 
criteria, in association with new immunohistochemical and PCR analyses of cardiac tissues. 
These new viral diagnostic approaches can lead to better identification of the aetiology of 
myocarditis and can improve the clinical or therapeutic monitoring of viral causes of human 
myocarditis. Therapeutic strategies adapted specifically to the phase of the disease are 
currently under evaluation and may improve prognosis and clinical outcomes significantly. 
It might be more efficient to use positive immunomodulators (interleukins, interferon alpha, 
interferon gamma) alone or in combination with specific antiviral components such as 
ribavirin in the initial phase of the disease when viral replication activity can be detected in 
the cardiomyocytes (Külh et al., 2003). By contrast, immunosuppressive drugs would be 
more appropriate in the chronic phase of myocarditis, when no or low viral replication 
activities are detectable in cardiac tissues by immunohistochemistry assays.  
Further specific strategies could consist to specifically block the entry of the virus in target 
cardiac cells, by preventing interaction of viruses with their cellular receptor and their 
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consequent signalling amplification systems, such as the tyrosine kinase p56lck, 
phosphatase CD45 and downstream ERK1/2 (Dennert et al., 2008). Preventing direct viral 
damage using antiviral therapy is another possible approach by use of specific viral drugs 
(anti-protease or inhibitors of RNA/DNA polymerases) or by use of general antiviral 
strategies (interfering RNA). Future randomized placebo-controlled trials should be based 
upon aetiological diagnosis (viral vs. other causes) and may provide novel treatment 
options and possibly a better prognosis for these selected patients. 
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